Third-generation continuous-flow left ventricular assist devices: a comparative outcome analysis by device type.

ABSTRACT:

Aims

Continuous-flow left ventricular assist devices (CF-LVADs) have become a standard of care in end-stage heart failure. Limited data exist comparing outcomes of HeartMate3 (HM3) and HeartWare HVAD (HW). We aimed to compare midterm outcomes of these devices.

Methods and results

Investigator-initiated retrospective-observational comparative analysis of all patients who underwent primary LVAD implantation of either HM3 or HW at our centre between January 2010 and December 2020. Data were derived from a prospective registry. Primary endpoints were all-cause mortality and heart transplantation. Secondary endpoints included device-related major adverse cardiac and cerebrovascular events, which included major bleeding, major neurological dysfunction (defined as persisting neurol

SUBMITTER: Mihalj M 

PROVIDER: S-EPMC9715830 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature